The EMERGE study met the primary endpoint, showing that patients treated with high dose (10mg/kg) of aducanumab experienced a statistically significant reduction in clinical decline of Alzheimerâ€™s disease.Other than Biogen, several large pharma companies, including Roche RHHBY, Amgen AMGN, Novartis NVS, Merck, Pfizer, Lilly and AstraZeneca stopped development of their AD candidates in the last few years either due to low possibility of success or safety concerns.